krn-7000 and Intestinal-Polyps

Murine and human invariant natural killer T (iNKT) lymphocytes are activated by α-galactosylceramide (α-GalCer) presented on CD1d. α-GalCer was first described as a lipid that had strong anti-metastatic effects in a mouse melanoma model, and it has subsequently been shown to induce efficient iNKT cell dependent tumor immunity in several tumor models. We have shown that α-GalCer treatment leads to a weak reduction of polyp burden in the autochthonous

Topics: Adenomatous Polyposis Coli Protein; Animals; Antibodies, Blocking; Colonic Neoplasms; Female; Galactosylceramides; Humans; Intestinal Mucosa; Intestinal Polyps; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Natural Killer T-Cells; Neoplasms, Experimental; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Th1 Cells

The glycosphingolipid α-galactosylceramide (α-GalCer) is a well-described immune activator with strong anti-tumor properties in animal models. It is presented on CD1d and acts by stimulating the invariant, type I, natural killer T (iNKT) lymphocytes to rapidly secrete TH1 and TH2 associated cytokines. This in turn promotes activation of a diversity of immune cells including natural killer (NK) cells with anti-tumor functions. Prior to tumor development, iNKT cells can also perform tumor surveillance and naturally protect from emergence of cancer. In contrast, we have recently demonstrated that iNKT cells naturally promote polyps in the spontaneous murine adenomatous polyposis coli (Apc)

Topics: Animals; Antigens, CD1d; CD8-Positive T-Lymphocytes; Cytokines; Female; Galactosylceramides; Immunosuppression Therapy; Immunotherapy; Inflammation; Intestinal Polyps; Ligands; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Natural Killer T-Cells; Neoplasms; Th1 Cells; Th2 Cells; Tumor Microenvironment